Echoiq Limited · ASX:EIQ
Echoiq — Investor Presentation (April 2022)
17 slides from Echoiq's investor presentation, Apr 28, 2022
Slide 1: Using the power of artificial intelligence to improve diagnosis in structural heart disease
Using the power of artificial intelligence to improve diagnosis in structural heart disease Company Presentation: April 28, 2022 Echo IQ (ASX:EIQ) echoiq.ai
Slide 2: Disclaimer and Forward Looking Statements
Disclaimer and Forward Looking Statements This presentation has been prepared by ECHOIQ Limited (Echo IQ). This document contains background information about Echo IQ current at the date of this presentation, 28 April 2022. The presentation is in summary form and does not purport to be all inclusive
Slide 3: Executive Summary
Executive Summary Rapid progress towards commercialisation Using AI to increase a market and delivery-platform already worth more than $4B per year, just in the US. Echo IQ (ASX:EIQ) is using artificial intelligence, data science Clinical studies and exclusive access to world-leading echocardiograph
Slide 4: Cardiovascular Disease remains the leading cause of death worldwide
Cardiovascular Disease remains the leading cause of death worldwide 650,000 Annual deaths in the US from heart disease (1) Every 13 minutes >50% of people with AS aren’t being Someone in Australia dies picked up (6) from heart attack (4) Only 36 seconds More than Since an American died from half car
Slide 5: Applying AI-backed data science to the identification of risk (structural heart)
Applying AI-backed data science to the identification of risk (structural heart) TODAY In Guideline Ex Guideline ESP-AS Echo IQ AI for Good WITH ESP-AS • Social impact • Patient re-assurance In Guideline • Enhanced diagnosis Ex Guideline • Better life outcomes • More opportunities to treat Measureme
Slide 6: Solution Backed by Exclusive access to world's leading cardiac database
Solution Backed by Exclusive access to world’s leading cardiac database 200M 1.2M Echocardiographic Patient records with output measurements ethnic diversity and and growing heart disease research rights disease (1) (1) 17 Years Mortality Exclusive commercial linked records enhance Valued research p
Slide 7: Progress Since Acquisition
Progress Since Acquisition June 2021 October 2021 February 2022 April 2022 Echo IQ Agreed Clinical Studies Med Tech Scientific Advisory acquired with St. Vincent’s appointments in Board with global Syd + Mel (funded by key commercial influencers Edwards Lifesciences) and regulatory roles Commercial
Slide 8: Focussed Investment and resource allocation: From an idea to a company focused on deployment
Focussed Investment and resource allocation: From an idea to a company focused on deployment New Scientific Advisory Board Updated algorithm 100% Echo IQ CMO invited to give plenary ESP-AS Design Files 90% address at WCE22 UI Prototyping 60% Self-funding US Trials & Studies beyond Integration Pilot
Slide 9: US Market Entry a Priority
US Market Entry a Priority World’s largest cardiology market Key appointments with US prioritised for commercial entry experience in MedTech commercialisation and regulation US Pilots defined: Engagement with ASCs*, Healthcare • US Data Review Pilot Systems, Device and Equipment • Health Economic Re
Slide 10: Commercialisation Approach: Retrospective Review
Commercialisation Approach Phase 1 – Retrospective Review Post-FDA Phase 1 ESP – Aortic Stenosis Market Seeding Commercial acceleration via ESP in Retrospective Mode in the first instance. Focus on market seeding. Focus on: ESP in Retrospective mode. • 90 x ASCs with cardiac specialty (Top 10 states
Slide 11: Commercialisation Approach: Real-Time Reporting
Commercialisation Approach Phase 2 – Real-Time Reporting Post-FDA Phase 2 ESP – Aortic Stenosis Increase commercial footprint by introducing ESP-AS in Real-Time Reporting mode. • 90 x ASCs • 200 x Regional Hospitals (Top 10 States) 38% • Large Hospitals/Groups (Top 10 States) US medical litigation d
Slide 12: Commercialisation Approach: Echo Hardware/Valve Makers/Additional Disease
Commercialisation Approach Phase 3 – Echo Hardware/Valve Makers/Additional Disease Post-FDA Phase 3 Integration of Echo IQ ESP into the Ultrasound hardware network to assist with better quality risk prediction at speed : Focus on key hardware manufacturers (eg): • Siemens • Philips • G/E Healthcare
Slide 13: FDA Timeframe 510(k) Pathway
FDA Timeframe 510(k) Pathway May Jun Jul Aug Sep Oct Nov Dec Jan Feb 2022 2022 2022 2022 2022 2022 2022 2022 2023 2023 Pre-Submission Documentation Pre-Submission Meeting • Request submission • Acceptance and scheduling • Feedback 510(k) Application • Draft • Review • Finalisation 510(k) Submission
Slide 14: Clinical Study (St. Vincent's Sydney & Melbourne)
Clinical Study (St. Vincent’s Sydney & Melbourne) Context PHASE 1 JACC Imaging Echo IQ Algorithm POC developed and refined 1 using machine learning, data science and imputation Original validation study on 330,000 records 2 Partners: successfully completed and published in JACC NEDA + Edwards LifeSc
Slide 15: Leadership Team
Leadership Team Andrew Grover Prof. Geoff Strange Deon Strydom Executive Chair & Managing Director Chief Research & Strategy Officer Chief Commercial Officer Leader of high-growth businesses in Faculty at University of Sydney Medical Experienced commercial leader in public and private operating Scho
Slide 16: New Scientific Advisory Board: Global Influencers and Thought-leaders
New Scientific Advisory Board: Global Influencers and Thought-leaders More than 1200 peer-reviewed publications Prof. Huon H. Gray, CBE MD Madeline Jankowski BS ACS Former Chairs and Presidents of the Former National Clinical Director CVD, RDCS FASE NHS England Am. College Cardiology and Am. Advance
Slide 17: Next Steps: Focused on Delivery
Next Steps: Focused on Delivery Product Deployment 1 Deliver a product that exceeds expectations, and integrates simply into existing workflows. 2 Regulation & Reimbursement Maintain corporate focus on a successful regulatory and reimbursement journey. Validation Studies 3 Complete Australian clinic